LC16m8

LC16m8

A smallpox vaccine licensed for use only in Japan.
References in periodicals archive ?
As important, the LC16m8 vaccine produced minimal local reactions and no severe adverse events, said Dr.
The researchers noted that while the total sample size in the study limited their ability to "conclusively confirm the absence of severe adverse events," their results support the conclusion that LC16m8 "causes minimal local manifestations and systemic adverse effects.
The third-generation smallpox vaccine LC16m8 was found to be as immunogenic as existing smallpox vaccines but appeared to be safer, according to a study of over 3,000 Japanese adults.
The five, attenuated, tissue-cultured LC16m8 vaccine proved to be immunogenic in adults who had never received any smallpox vaccination, and it also produced an adequate booster response in those who had been vaccinated previously.
They assessed the LC16m8 vaccine in healthy personnel in the Japan Self-Defense Forces inoculated in 2002-2005.
The researchers noted that while the total sample size in the study limited their ability to "conclusively confirm that absence of severe adverse events," their results support the conclusion that LC16m8 "causes minimal local manifestations and systemic adverse effects.
They gave single shots of the LC16m8 vaccine--which uses a live, attenuated virus--to 3,221 participants from the Japan Self-Defense Forces between 2002 and 2005, wrote the researchers, led by Tomoya Saito of Keio University in Tokyo.
The LC16m8 strain had a take rate of 95% (compared with 93.
Montoya's group is comparing an investigational vaccine -- LC16m8, developed by California-based VaxGen, Inc.
Unlike Dryvax, which is made from live virus, LC16m8 has been attenuated, or modified.
Although LC16m8 is already licensed in Japan and has been used successfully to vaccinate more than 50,000 children there, U.
The participants will be randomly assigned to receive LC16m8 or Dryvax.